NCCN News

Restricted access
  • 1.

    Bahleda R, Meric-Bernstam F, Goyal L, . Phase 1, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors [published online July 2, 2020]. Ann Oncol, doi:10.1016/j.annonc.2020.06.018

    • Search Google Scholar
    • Export Citation
  • 1.

    Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. RAND Corporation. Accessed July 10, 2020. Available at: https://www.rand.org/pubs/perspectives/PE264.html

    • Search Google Scholar
    • Export Citation

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 35 35 3
PDF Downloads 25 25 5
EPUB Downloads 0 0 0